Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | C1R | P00736 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150548 | 0.86 | C5AR1 (0.83) | C5AR1CYP2C9CYP2C18CA12CA9 | |
| SCHEMBL13649261 | 0.86 | C5AR1 (0.65) | C5AR1CA12CA9LMNATSHR | |
| SCHEMBL5121853 | 0.85 | C5AR1 (0.59) | C5AR1CYP2C9CYP2C8CYP2C18CA12 | |
| SCHEMBL17174236 | 0.83 | C5AR1 (0.62) | C5AR1CYP2C9CA12CA9LMNA | |
| SCHEMBL15756100 | 0.83 | C5AR1 (0.62) | C5AR1CA12CA9LMNATSHR | |
| SCHEMBL17174226 | 0.83 | C5AR1 (0.62) | C5AR1CA12CA9LMNATSHR | |
| SCHEMBL24125234 | 0.82 | C5AR1 (0.56) | C5AR1CYP2C9CYP2C8CYP2C18C1R | |
| SCHEMBL17174232 | 0.81 | KEAP1 (0.70) | C5AR1CYP2C9LMNAC1RKEAP1 | |
| SCHEMBL17174225 | 0.80 | C5AR1 (0.57) | C5AR1CA12CA9LMNATSHR | |
| SCHEMBL17174229 | 0.80 | C5AR1 (0.57) | C5AR1CA12CA9LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | C5AR1 4571/4885CYP2C9 4363/4885CYP2C8 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.